3rd TIGIT Axis Therapies (description)


Address:Virtual Event , , United States of America
Event dates:12/7/2022 - 12/8/2022 (This event has already taken place)
Event web site:
findCE GPA: This event is not yet rated. Click here to view a sample report card
Click here to rate 3rd TIGIT Axis Therapies


Topics to be Covered:

  • Murali Ramachandra, Chief Executive Officer, Aurigene Discovery Technologies
  • David Wald, Associate Professor, Case Western Reserve University
  • Leonie Meima, Vice President Business Development, Coherus Biosciences
  • Eran Ophir, Senior Vice President Research and Drug Discovery, Compugen
  • William Freed-Pastor, Instructor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School
  • Pharmaceuticals
Organizer phone:+4402031418700
Offering type:Conference
Specialty:Data not provided
Event frequency:Never
First Meeting:
Total events:
Est. attendance:
Target audience:Any
Other target audiences:
Host Sponsor:Hanson Wade
Est. # of exhibitors:
Currency:US Dollars
CE Credits:
Organizer URL


As immuno-oncology drug development transforms cancer treatment paradigms, preclinical and clinical data continues to demonstrate that the TIGIT axis blockade, particularly in combination with other immune checkpoint inhibitor partners, has strong efficacy. Despite recent clinical setbacks, and with at least 15 anti-TIGIT axis drugs in active clinical development, TIGIT axis targeting remains a promising treatment approach.

In the context of a need to accelerate practice-changing cancer immunotherapies towards approval and to patients in need, the 3rd TIGIT Axis Therapies Summit returns to reunite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting.

Covering deciphering the mechanistic intricacies underlying TIGIT axis signaling, defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines, exploring novel drug designs in terms of Fc functionality and IgG type, identifying molecular signatures relevant to the tumor microenvironment and periphery to incorporating unique pharmacology properties into trial design, this is your comprehensive guide for addressing the unique challenges of TIGIT axis targeted drug development and powering up your pipelines.

This year's sharp two-day agenda leans into the clinical headwinds faced by so many immune checkpoint targets. As the space regroups, join the conversation to build meaningful partnerships and maximize the clinical and commercial success of the next generation of TIGIT axis targeted drugs.

Earlybird and team discounts available!


Time: 8:00 am to 5:00 pm

Registration Fee Details:

Conference Only - Industry Pricing - On the Day : USD 2299.00,
Conference Only - Academic Pricing - On the Day: USD 2099.00,
Conference Only - Service and Solution Provider Pricing - On the Day: USD 2799.00

Other items that tuition includes:

Travel and hotel arrangements:

Contact Person:Ellie Saunders
Organizer State/Province: (Outside US)
Organizer CountryData not provided
Organizer Phone+4402031418700
Structural makeupData not provided
Host Sponsor; Other SponsorsHanson Wade
Event Site/VenueVirtual Event
Event sold out?No
Multiple locations or dates?No
Statistics available for most recent event held in:NA
Average number in event attendance of:
Number in attendance of:
Target BoundariesInternational
Is Registration contact information the same as Organizer Contact above?Yes
Web Page
Can one register for your CE on your web site?NA
Can registration be made by snail (regular) mail?Yes
Online housing reservations: 
Do you have additional written or AV materials for sale?No
If so, are they available for non-attendees as well as those attending?NA
Is full tuition necessary to ensure registration?No
Will there be shuttle service available?NA
Additional notes:

Sign In/Sign Out
About Us
Contact Us